Trypanosoma cruzi: Does the intake of nanoencapsulated benznidazole control acute infections?

Chagas Disease (CD) affects around eight million people worldwide. It is considered a neglected disease that presents few treatment options with efficacy only in the acute phase. Nanoparticles have many positive qualities for treating parasite infections and may be effectively and widely employed in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Experimental parasitology 2023-06, Vol.249, p.108520-108520, Article 108520
Hauptverfasser:	Dutra da Silva, Aniélen, Fracasso, Mateus, Bottari, Nathieli B., Gundel, Samanta, Ourique, Aline F., Assmann, Charles E., Ferreira, Danielle A.S.P., Castro, Milagros F.V., Reichert, Karine P., de Souza, Lucas A.F., da Veiga, Marcelo L., da Rocha, Maria Izabel U.M., Monteiro, Silvia G., Morsch, Vera M., Chitolina Schetinger, Maria Rosa, da Silva, Aleksandro S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute phase Animals Chagas disease Chagas Disease - parasitology Female Mice Nanocapsules Nitroimidazoles - pharmacology Nitroimidazoles - therapeutic use Parasitemia - drug therapy Parasitemia - parasitology Pathogenesis Treatment Trypanocidal Agents - pharmacology Trypanocidal Agents - therapeutic use Trypanosoma cruzi
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!